These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 38162648)

  • 1. A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease.
    Martínez-Sanz J; Talavera-Rodríguez A; Díaz-Álvarez J; Rosas Cancio-Suárez M; Rodríguez JM; Alba C; Montes ML; Martín-Mateos R; Burgos-Santamaría D; Moreno S; Serrano-Villar S; Sánchez-Conde M
    Front Immunol; 2023; 14():1297378. PubMed ID: 38162648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations of the duodenal mucosal microbiome in patients with metabolic dysfunction-associated steatotic liver disease.
    Ren M; Pan H; Zhou X; Yu M; Ji F
    Sci Rep; 2024 Apr; 14(1):9124. PubMed ID: 38643212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut microbiota-based machine-learning signature for the diagnosis of alcohol-associated and metabolic dysfunction-associated steatotic liver disease.
    Park IG; Yoon SJ; Won SM; Oh KK; Hyun JY; Suk KT; Lee U
    Sci Rep; 2024 Jul; 14(1):16122. PubMed ID: 38997279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct Gut Microbial Signature and Host Genetic Variants in Association with Liver Fibrosis Severity in Patients with MASLD.
    Satthawiwat N; Jinato T; Sutheeworapong S; Tanpowpong N; Chuaypen N; Tangkijvanich P
    Nutrients; 2024 Jun; 16(12):. PubMed ID: 38931155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of gut barrier integrity and host-microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus.
    Forlano R; Martinez-Gili L; Takis P; Miguens-Blanco J; Liu T; Triantafyllou E; Skinner C; Loomba R; Thursz M; Marchesi JR; Mullish BH; Manousou P
    Gut Microbes; 2024; 16(1):2304157. PubMed ID: 38235661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the oral and gut microbiome in children with obesity aged 3 to 5 years.
    Ma T; Wu Z; Lin J; Shan C; Abasijiang A; Zhao J
    Front Cell Infect Microbiol; 2023; 13():1102650. PubMed ID: 37065198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COMPARISON OF GUT MICROBIOTA IN ALCOHOLIC AND METABOLIC-DYSFUNCION ASSOCIATED STEATOTIC LIVER DISEASE IN ANIMAL MODELS.
    Perlin CM; Longo L; Thoen RU; Uribe-Cruz C; Álvares-DA-Silva MR
    Arq Gastroenterol; 2024; 61():e23100. PubMed ID: 38511793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between Diet, the Gut Microbiome, and Short-Chain Fatty Acid Production among Older Caribbean Latino Adults.
    Maldonado-Contreras A; Noel SE; Ward DV; Velez M; Mangano KM
    J Acad Nutr Diet; 2020 Dec; 120(12):2047-2060.e6. PubMed ID: 32798072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alteration of Gut Microbiota Composition in the Progression of Liver Damage in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Zazueta A; Valenzuela-Pérez L; Ortiz-López N; Pinto-León A; Torres V; Guiñez D; Aliaga N; Merino P; Sandoval A; Covarrubias N; Pérez de Arce E; Cattaneo M; Urzúa A; Roblero JP; Poniachik J; Gotteland M; Magne F; Beltrán CJ
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut Microbiota May Play a Significant Role in the Pathogenesis of Graves' Disease.
    Jiang W; Yu X; Kosik RO; Song Y; Qiao T; Tong J; Liu S; Fan S; Luo Q; Chai L; Lv Z; Li D
    Thyroid; 2021 May; 31(5):810-820. PubMed ID: 33234057
    [No Abstract]   [Full Text] [Related]  

  • 11. Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments.
    Pirola CJ; Landa MS; Schuman M; García SI; Salatino A; Sookoian S
    Clin Mol Hepatol; 2024 Oct; ():. PubMed ID: 39391907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in the gut microbiota of patients with acquired immune deficiency syndrome.
    Zhou Y; Ou Z; Tang X; Zhou Y; Xu H; Wang X; Li K; He J; Du Y; Wang H; Chen Y; Nie Y
    J Cell Mol Med; 2018 Apr; 22(4):2263-2271. PubMed ID: 29411528
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Mak AL; Augustijn QJJ; Heymann CJF; Havik S; Verdoes X; Rios-Morales M; Bosmans LA; Verheij J; Meijnikman AS; de Jonge PA; Herrema H; de Vos WM; Nieuwdorp M; Grefhorst A; Holleboom AG
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population-based metagenomics analysis reveals altered gut microbiome in sarcopenia: data from the Xiangya Sarcopenia Study.
    Wang Y; Zhang Y; Lane NE; Wu J; Yang T; Li J; He H; Wei J; Zeng C; Lei G
    J Cachexia Sarcopenia Muscle; 2022 Oct; 13(5):2340-2351. PubMed ID: 35851765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microbiota modulation by dietary oat beta-glucan prevents steatotic liver disease progression.
    Jaeger JW; Brandt A; Gui W; Yergaliyev T; Hernández-Arriaga A; Muthu MM; Edlund K; Elashy A; Molinaro A; Möckel D; Sarges J; Halibasic E; Trauner M; Kahles F; Rolle-Kampczyk U; Hengstler J; Schneider CV; Lammers T; Marschall HU; von Bergen M; Camarinha-Silva A; Bergheim I; Trautwein C; Schneider KM
    JHEP Rep; 2024 Mar; 6(3):100987. PubMed ID: 38328439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silymarin decreases liver stiffness associated with gut microbiota in patients with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, placebo-controlled trial.
    Jin Y; Wang X; Chen K; Chen Y; Zhou L; Zeng Y; Zhou Y; Pan Z; Wang D; Li Z; Liang Y; Ling W; Li D
    Lipids Health Dis; 2024 Aug; 23(1):239. PubMed ID: 39097726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiological Study on the Interaction between the
    Sato S; Iino C; Sasada T; Soma G; Furusawa K; Yoshida K; Sawada K; Mikami T; Nakaji S; Sakuraba H; Fukuda S
    Genes (Basel); 2024 Sep; 15(9):. PubMed ID: 39336763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NAD metabolic therapy in metabolic dysfunction-associated steatotic liver disease: Possible roles of gut microbiota.
    Lu X; Yang R; Chen Y; Chen D
    iScience; 2024 Mar; 27(3):109174. PubMed ID: 38405608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut Microbiome-How Does Two-Month Consumption of Fiber-Enriched Rolls Change Microbiome in Patients Suffering from MASLD?
    Kaźmierczak-Siedlecka K; Maciejewska-Markiewicz D; Sykulski M; Gruszczyńska A; Herman-Iżycka J; Wyleżoł M; Katarzyna Petriczko K; Palma J; Jakubczyk K; Janda-Milczarek K; Skonieczna-Żydecka K; Stachowska E
    Nutrients; 2024 Apr; 16(8):. PubMed ID: 38674864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Markers of metabolic health and gut microbiome diversity: findings from two population-based cohort studies.
    Zouiouich S; Loftfield E; Huybrechts I; Viallon V; Louca P; Vogtmann E; Wells PM; Steves CJ; Herzig KH; Menni C; Jarvelin MR; Sinha R; Gunter MJ
    Diabetologia; 2021 Aug; 64(8):1749-1759. PubMed ID: 34110438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.